Is Serous Cystadenoma of the Pancreas a Model of Clear-Cell-Associated Angiogenesis and Tumorigenesis?
- 1 January 2009
- journal article
- Published by Elsevier in Pancreatology
- Vol. 9 (1-2) , 182-188
- https://doi.org/10.1159/000178890
Abstract
Similar to the other von Hippel-Lindau (VHL)-related tumors such as renal cell carcinomas and capillary hemangioblastomas, serous cystadenomas (SCAs) of the pancreas are also characterized by clear cells. Over the years, we have also noticed that the tumor epithelium shows a prominent capillary network. Eighteen cases of SCA were reviewed histologically, and immunohistochemical analysis was performed for CD31 and vascular endothelial growth factor (VEGF) as well as the molecules implicated in clear-cell tumorigenesis: GLUT-1, hypoxia-inducible factor-1 (HIF-1alpha), and carbonic anhydrase IX (CA IX). There was an extensively rich capillary network that appears almost intraepithelially in all cases of SCA, which was confirmed by CD31 stain that showed, on average, 26 capillaries per every 100 epithelial cells. VEGF expression was identified in 10/18 cases. Among the clear-cell tumorigenesis markers, CA IX was detected in all cases, GLUT-1 and HIF-1alpha in most cases. As in other VHL-related clear-cell tumors, there is a prominent capillary network immediately adjacent to the epithelium of SCA, confirming that the clear-cell- angiogenesis association is also valid for this tumor type. Molecules implicated in clear-cell tumorigenesis are also consistently expressed in SCA. This may have biologic and therapeutic implications, especially considering the rapidly evolving drugs against these pathways. More importantly, SCA may also serve as a model of clear-cell-associated angiogenesis and tumorigenesis, and the information gained from this tumor type may also be applicable to other clear-cell tumors.Keywords
This publication has 49 references indexed in Scilit:
- The Potential of Antiangiogenic Therapy in Non–Small Cell Lung CancerClinical Cancer Research, 2007
- Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapyExpert Opinion on Biological Therapy, 2007
- Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignanciesClinical Therapeutics, 2006
- An Immunohistochemical and Ultrastructural Study of Pancreatic Microcystic Serous Cyst Adenoma with Special Reference to Tumor-Associated Microvasculature and Vascular Endothelial Growth Factor in Tumor CellsUltrastructural Pathology, 2006
- The role of carbonic anhydrase IX overexpression in kidney cancerEuropean Journal Of Cancer, 2005
- Serous Cystadenoma of the PancreasAnnals of Surgery, 2005
- RETRACTED: Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activitySurgery, 2004
- Clinical Significance of Glucose Transporter 1 (GLUT1) Expression in Human Breast CarcinomaJapanese Journal of Cancer Research, 2002
- Histopathology and Molecular Genetics of Multiple Cysts and Microcystic (Serous) Adenomas of the Pancreas in von Hippel-Lindau PatientsThe American Journal of Pathology, 2000
- Over-expression of facilitative glucose transporter genes in human cancerBiochemical and Biophysical Research Communications, 1990